You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20-CART

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory Trial in Cologne,

Active, not recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • +3 more
  • MB-CART20.1
  • Cologne, Germany
  • +1 more
Sep 20, 2021

Melanoma (Skin) Trial in Cologne (MB-CART20.1)

Recruiting
  • Melanoma (Skin)
  • MB-CART20.1
  • Cologne, NRW, Germany
    University Hospital of Cologne - Clinic for Internal Medicine I
Sep 20, 2021

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Study for Patients Treat With WU-CART-007

Enrolling by invitation
  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma
  • Genetic: WU-CART-007
  • Saint Louis, Missouri
    Washington University
Aug 18, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

Not yet recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoma, Non-Hodgkin
  • CART-19
  • Ribeirao Preto, Sao Paulo, Brazil
    Ribeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023

Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma (MM)
  • 3x10(6) CART-38 cellls
  • +5 more
  • (no location specified)
Jul 15, 2022

HBV Reactivation in Anti CD20 Treatment

Active, not recruiting
  • Hepatitis B
    • Afula, Tsafon, Israel
      HaEmek Medical Center
    Mar 14, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

    Recruiting
    • CD20-positive Non-Hodgkin Lymphoma
    • EX103 injection
    • Zhengzhou, Henan, China
    • +3 more
    Aug 28, 2023

    Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ublituximab
    • Fort Collins, Colorado
    • +1 more
    May 26, 2023

    Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

    Not yet recruiting
    • Nephrotic Syndrome
    • Genova, Italy
      IRCCS G. Gaslini
    Jan 19, 2023